Status: Recruiting
This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors
This is a first-in-human, Phase 1, multi-center, open-label study to characterize the safety, pharmacokinetics, pharmacodynamics, and preliminary anti tumor activity of LTZ-232 as monotherapy in adult participants with unresectable or metastatic colorectal cancer and other solid tumors failing standard therapies.
Participants needed: 152
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: LTZ Therapeutics, Inc.Updated: Nov 3, 2026Locations: 1
Eligibility criteria
Advanced /metastatic colorectal tumors that have failed standard treatments [+3]
Active infection with hepatitis B or C [+6]